7 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 5 Phase 2, 4 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Completed 3, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Chronic Phase Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Phase Chronic Myeloid Leukemia trials Research Report on Chronic Phase Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Ruxolitinib, BCR-ABL Tyrosine Kinase Inhibitor (TKI) - Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2019-11-19 | 2026-04-02 |
| Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States Chronic Phase Chronic Myeloid Leukemia | Completed | Bristol-Myers Squibb | 118 | 2017-07-19 | 2022-12-21 | |
| A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID - Chronic Phase Chronic Myeloid Leukemia | Phase 3 | Terminated | Ariad Pharmaceuticals | 44 | 2015-12-31 | 2021-11-26 |
| Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 2 | Completed | Bristol-Myers Squibb | 84 | 2014-01-22 | 2022-11-03 |
| Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response P1101 - Chronic Phase Chronic Myeloid Leukemia | Phase 1 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 12 | 2013-08-30 | 2019-01-04 |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 4 | 2013-08-01 | 2020-11-02 |
| Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 11 | 2013-02-21 | 2021-01-05 |
| Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 4 | Completed | Bristol-Myers Squibb | 39 | 2012-12-01 | 2016-11-22 |
| Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Imatinib, Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 2 | Completed | Bristol-Myers Squibb | 262 | 2012-09-12 | 2023-06-22 |
Leukemia, Myeloid, Chronic-Phase (10) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Blast Crisis (2) · Leukemia (2) · Leukemia, Myeloid, Accelerated Phase (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Leukemia, Myeloid (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Chronic Disease (10) · Disease Attributes (10) · Hemic and Lymphatic Diseases (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Bone Marrow Diseases (9) · Hematologic Diseases (9) · Leukemia, Myeloid (9) · Myeloproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Leukemia (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Carcinogenesis (2) · Cell Transformation, Neoplastic (2)
Dasatinib (3) · nilotinib (3) · ruxolitinib (3) · ponatinib (2) · BID protein, human (1) · Imatinib Mesylate (1) · peginterferon alfa-2b (1)
Bristol-Myers Squibb (4) · H. Lee Moffitt Cancer Center and Research Institute (2) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Ariad Pharmaceuticals (1) · Incyte Biosciences International Sàrl (1) · University Health Network, Toronto (1)
United States (6) · France (4) · Italy (4) · Belgium (3) · Canada (3) · Spain (3) · Austria (2) · Germany (2) · South Korea (2) · Argentina (1) · Brazil (1) · China (1) · Czechia (1) · Hungary (1) · Netherlands (1)
Dennis Kim, MD/PhD (1) · Javier Pinilla-Ibarz, MD, PhD (1) · Josef Thaler, MD (1) · Kendra Sweet, M.D. (1) · Mohammed-El-Amine Bensmaine, MD (1)
PMID 30340199, PMID 32265500, PMID 37246588
2015 (1), 2018 (1), 2023 (1)